Revumenib (SNDX-5613)

Menin Inhibitor
Phase 1
Phase 2
Pivotal
Registration
Indication(s)
BEAT-AML
(venetoclax/azacitidine combo)
Frontline KMT2Ar and
NPM1m AML
INTERCEPT
(monotherapy)
MRD- progression in
KMT2Ar and NPM1m AML
Colorectal Cancer
(monotherapy)
Unresectable metastatic
microsatellite stable CRC

Axatilimab (SNDX-6352)

Anti-CSF-1R mAB
Phase 1
Phase 2
Pivotal
Registration
Indication(s)

Entinostat (SNDX-275)

Class 1 HDAC Inhibitor
Phase 1
Phase 2
Pivotal
Registration
Indication(s)

Revumenib (SNDX-5613)

Menin Inhibitor

BEAT-AML

Frontline KMT2Ar and NPM1m AML

Phase 1

INTERCEPT

MRD- progression in KMT2Ar and NPM1m AML

Phase 1

Colorectal Cancer

Unresectable metastatic microsatellite stable CRC

Phase 1

Axatilimab (SNDX-6352)

Anti-CSF-1R mAB

Entinostat (SNDX-275)

Class 1 HDAC Inhibitor

*Submission of registrational filing expected by year-end 2023